Cargando…

Association of Mineralocorticoid Receptor Antagonists With the Mortality and Cardiovascular Effects in Dialysis Patients: A Meta-analysis

Whether Mineralocorticoid receptor antagonists (MRA) reduce mortality and cardiovascular effects of dialysis patients remains unclear. A meta-analysis was designed to investigate whether MRA reduce mortality and cardiovascular effects of dialysis patients, with a registration in INPLASY (INPLASY2020...

Descripción completa

Detalles Bibliográficos
Autores principales: Gou, Wen-Jun, Zhou, Fa-Wei, Providencia, Rui, Wang, Bo, Zhang, Heng, Hu, Shou-Liang, Gao, Xiao-Li, Tuo, Yan-hong, Zhang, Yong, Li, Tian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152260/
https://www.ncbi.nlm.nih.gov/pubmed/35656294
http://dx.doi.org/10.3389/fphar.2022.823530
_version_ 1784717607635517440
author Gou, Wen-Jun
Zhou, Fa-Wei
Providencia, Rui
Wang, Bo
Zhang, Heng
Hu, Shou-Liang
Gao, Xiao-Li
Tuo, Yan-hong
Zhang, Yong
Li, Tian
author_facet Gou, Wen-Jun
Zhou, Fa-Wei
Providencia, Rui
Wang, Bo
Zhang, Heng
Hu, Shou-Liang
Gao, Xiao-Li
Tuo, Yan-hong
Zhang, Yong
Li, Tian
author_sort Gou, Wen-Jun
collection PubMed
description Whether Mineralocorticoid receptor antagonists (MRA) reduce mortality and cardiovascular effects of dialysis patients remains unclear. A meta-analysis was designed to investigate whether MRA reduce mortality and cardiovascular effects of dialysis patients, with a registration in INPLASY (INPLASY2020120143). The meta-analysis revealed that MRA significantly reduced all-cause mortality (ACM) and cardiovascular mortality (CVM). Patients receiving MRA presented improved left ventricular mass index (LVMI) and left ventricular ejection fraction (LVEF), decreased systolic blood pressure (SBP) and diastolic blood pressure (DBP). There was no significant difference in the serum potassium level between the MRA group and the placebo group. MRA vs. control exerts definite survival and cardiovascular benefits in dialysis patients, including reducing all-cause mortality and cardiovascular mortality, LVMI, and arterial blood pressure, and improving LVEF. In terms of safety, MRA did not increase serum potassium levels for dialysis patients with safety. Systematic Review Registration: (https://inplasy.com/inplasy-protocol-1239-2/), identifier (INPLASY2020120143).
format Online
Article
Text
id pubmed-9152260
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91522602022-06-01 Association of Mineralocorticoid Receptor Antagonists With the Mortality and Cardiovascular Effects in Dialysis Patients: A Meta-analysis Gou, Wen-Jun Zhou, Fa-Wei Providencia, Rui Wang, Bo Zhang, Heng Hu, Shou-Liang Gao, Xiao-Li Tuo, Yan-hong Zhang, Yong Li, Tian Front Pharmacol Pharmacology Whether Mineralocorticoid receptor antagonists (MRA) reduce mortality and cardiovascular effects of dialysis patients remains unclear. A meta-analysis was designed to investigate whether MRA reduce mortality and cardiovascular effects of dialysis patients, with a registration in INPLASY (INPLASY2020120143). The meta-analysis revealed that MRA significantly reduced all-cause mortality (ACM) and cardiovascular mortality (CVM). Patients receiving MRA presented improved left ventricular mass index (LVMI) and left ventricular ejection fraction (LVEF), decreased systolic blood pressure (SBP) and diastolic blood pressure (DBP). There was no significant difference in the serum potassium level between the MRA group and the placebo group. MRA vs. control exerts definite survival and cardiovascular benefits in dialysis patients, including reducing all-cause mortality and cardiovascular mortality, LVMI, and arterial blood pressure, and improving LVEF. In terms of safety, MRA did not increase serum potassium levels for dialysis patients with safety. Systematic Review Registration: (https://inplasy.com/inplasy-protocol-1239-2/), identifier (INPLASY2020120143). Frontiers Media S.A. 2022-05-17 /pmc/articles/PMC9152260/ /pubmed/35656294 http://dx.doi.org/10.3389/fphar.2022.823530 Text en Copyright © 2022 Gou, Zhou, Providencia, Wang, Zhang, Hu, Gao, Tuo, Zhang and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Gou, Wen-Jun
Zhou, Fa-Wei
Providencia, Rui
Wang, Bo
Zhang, Heng
Hu, Shou-Liang
Gao, Xiao-Li
Tuo, Yan-hong
Zhang, Yong
Li, Tian
Association of Mineralocorticoid Receptor Antagonists With the Mortality and Cardiovascular Effects in Dialysis Patients: A Meta-analysis
title Association of Mineralocorticoid Receptor Antagonists With the Mortality and Cardiovascular Effects in Dialysis Patients: A Meta-analysis
title_full Association of Mineralocorticoid Receptor Antagonists With the Mortality and Cardiovascular Effects in Dialysis Patients: A Meta-analysis
title_fullStr Association of Mineralocorticoid Receptor Antagonists With the Mortality and Cardiovascular Effects in Dialysis Patients: A Meta-analysis
title_full_unstemmed Association of Mineralocorticoid Receptor Antagonists With the Mortality and Cardiovascular Effects in Dialysis Patients: A Meta-analysis
title_short Association of Mineralocorticoid Receptor Antagonists With the Mortality and Cardiovascular Effects in Dialysis Patients: A Meta-analysis
title_sort association of mineralocorticoid receptor antagonists with the mortality and cardiovascular effects in dialysis patients: a meta-analysis
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152260/
https://www.ncbi.nlm.nih.gov/pubmed/35656294
http://dx.doi.org/10.3389/fphar.2022.823530
work_keys_str_mv AT gouwenjun associationofmineralocorticoidreceptorantagonistswiththemortalityandcardiovasculareffectsindialysispatientsametaanalysis
AT zhoufawei associationofmineralocorticoidreceptorantagonistswiththemortalityandcardiovasculareffectsindialysispatientsametaanalysis
AT providenciarui associationofmineralocorticoidreceptorantagonistswiththemortalityandcardiovasculareffectsindialysispatientsametaanalysis
AT wangbo associationofmineralocorticoidreceptorantagonistswiththemortalityandcardiovasculareffectsindialysispatientsametaanalysis
AT zhangheng associationofmineralocorticoidreceptorantagonistswiththemortalityandcardiovasculareffectsindialysispatientsametaanalysis
AT hushouliang associationofmineralocorticoidreceptorantagonistswiththemortalityandcardiovasculareffectsindialysispatientsametaanalysis
AT gaoxiaoli associationofmineralocorticoidreceptorantagonistswiththemortalityandcardiovasculareffectsindialysispatientsametaanalysis
AT tuoyanhong associationofmineralocorticoidreceptorantagonistswiththemortalityandcardiovasculareffectsindialysispatientsametaanalysis
AT zhangyong associationofmineralocorticoidreceptorantagonistswiththemortalityandcardiovasculareffectsindialysispatientsametaanalysis
AT litian associationofmineralocorticoidreceptorantagonistswiththemortalityandcardiovasculareffectsindialysispatientsametaanalysis